Still ‘Work To Be Done’ After Ranibizumab Approval, Says Samsung Bioepis

Executive Kyung-Ah Kim Sees Opportunity To Lead On Ophthalmic Biosimilars

Eye USA Flag Face
Samsung Bioepis recently gained the first US ophthalmic biosimilar approval • Source: Alamy

More from Biosimilars

More from Products